CLIMB BIO, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
CLIMB BIO, INC. (CLYM) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $2.66 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- CLIMB BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $3.04.
- CLIMB BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.32, a 65900.00% increase year-over-year.
- CLIMB BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.00.
- CLIMB BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $3.04, a 25.85% decline from fiscal 2024.
- CLIMB BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $4.10, a 439.47% increase from fiscal 2023.
- CLIMB BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $0.76.
- CLIMB BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.66 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $3.04 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $3.04 10-K · filed 2026-03-05 | |||
| 2024-12-31 | $4.10 10-K · filed 2025-03-25 | |||
| 2024-09-30 | $4.11 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $3.84 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $1.32 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | $0.76 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $0.62 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $0.06 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $0.00 10-K · filed 2023-03-06 | |||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-15 | |||
| 2021-12-31 | $1.88 10-K · filed 2022-03-07 | |||
| 2021-09-30 | $1.86 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $1.86 10-Q · filed 2021-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |